Organisation paid for research Program year 2025 Source: CMS Open Payments

IM Super Holdings LLC dba IMA Evaluations LLC

Neither a doctor nor a teaching hospital

Research payments

$1,980,600

170 payments

Through program year 2025, IM Super Holdings LLC dba IMA Evaluations LLC is reported as receiving $1,980,600 in research payments, across 170 payments.

By program year

2 rows
Year Kind Amount Payments
2025 Research $754,815 128
2024 Research $1,225,784 42

Breakdown

Who paid Research payments · program years 2024–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $1,725,303 137 payments
  2. Supernus Pharmaceuticals, Inc. $255,297 33 payments
Studies the money was for Research payments · program years 2024–2025
  1. Obesity Long term safety in patients with CV risk $871,400 5 payments
  2. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $630,167 109 payments
  3. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression $255,297 33 payments
  4. A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. $92,316 7 payments
  5. Roll-over bronchiectasis $69,631 12 payments
  6. CatC inhibitor Phase II in bronchiectasis $25,213 1 payment
  7. Hepatic Impairment Study $23,541 1 payment
  8. A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) $13,035 2 payments
What the money was spent on Research payments · program years 2024–2025
  1. Patient care $255,297 33 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record